- Conditions
- Nonalcoholic Steatohepatitis (NASH) With Fibrosis
- Interventions
- Elafibranor, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo Matched to Elafibranor 80 mg, Placebo Matched to Elafibranor 120 mg
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 30
- States / cities
- Lancaster, California • Los Angeles, California • Sacramento, California + 26 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Elafibranor, Placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 20
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Healthy Volunteers
- Interventions
- Elafibranor
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Long Beach, California • Los Alamitos, California
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor 80 mg, Elafibranor 120 mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
- Conditions
- Non Alcoholic Steatohepatitis
- Interventions
- Elafibranor 80mg, Elafibranor 120mg
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- San Diego, California • New York, New York
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor, Placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Coronado, California • Colorado Springs, Colorado + 10 more
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- GFT505 80mg, GFT505 120mg, Placebo
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 19
- States / cities
- Fresno, California • La Jolla, California • Aurora, Colorado + 15 more
- Conditions
- Primary Biliary Cholangitis (PBC)
- Interventions
- Elafibranor, Matched 80 mg placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 42
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more
- Conditions
- Pregnancy Related
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Female only
- Enrollment
- 3 participants
- Timeline
- 2026 – 2039
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Elafibranor 80mg, Placebo
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 20
- States / cities
- Coronado, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Hepatic Impairment, Liver Disease, Pharmacokinetics
- Interventions
- Elafibranor
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Miami, Florida